Table 1 Dosage information in FA supplementation and it’s relation with CHD or ASD

Scanlon KS et al. (1998) [18]

Low-dose group < 245 μg

1.11 (0.63, 2.00)

Middle-dose group 245–355 μg

1

High-dose group 356–542 μg

1.30 (0.78, 2.22)

Shaw GM et al. (2010) [20]

Low-dose group < 293.8 μg

1.45 (0.87, 2.41)

Middle-dose group 293.8–546.3 μg

1

High-dose group ≥ 546.4 μg

0.74 (0.41, 1.31)

Czeizel AE et al. (2015) [25]

Low-dose group 3 mg

1.06 (0.78, 1.44)

1.49 (0.65, 3.41)

Middle-dose group 6 mg

1

1

High-dose group 9 mg

1.14 (0.71, 1.81)

1.81 (0.51, 6.42)

Mao B et al. (2017) [34]

Low -dose group < 149.88 μg

1.63 (1.01, 2.62)

1.44 (0.72, 2.87)

Middle-dose group 149.88–266.35 μg

1

1

High-dose group ≥ 266.35 μg

1.06 (0.62, 1.81)

1.07 (0.50, 2.25)